Finish Line Inc. (FINL) Jumps 8.66% on December 22

Equities Staff |

Finish Line Inc. (FINL) was among the biggest gainers on the Russell 2000 for Tuesday December 22 as the stock popped 8.66% to $18.20, representing a gain of $1.45 per share. Some 2.06 million shares traded hands on 13,439 trades, compared with an average daily volume of 1.18 million shares out of a total float of 44.85 million. The stock opened at $17.50 and traded with an intraday range of $18.30 to $16.96.

After today's gains, Finish Line Inc. reached a market cap of $816.2 million. Finish Line Inc. has had a trading range between $29.05 and $15.37 over the last year, and it had a 50-day SMA of $17.40 and a 200-day SMA of $23.38.

The stock has a P/E Ratio of 9.5.

Finish Line Inc is a mall-based specialty retailer in the United States, and operates two retail divisions under the Finish Line brand name Finish Line and Running Specialty Group.

Finish Line Inc. is based out of Indianapolis, IN and has some 12,300 employees. Its CEO is Glenn S. Lyon.

For a complete fundamental analysis analysis of Finish Line Inc., check out Equities.com’s Stock Valuation Analysis report for FINL. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Trustify

Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…

Lyft

Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…